Flexion Therapeutics’ FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis, Receives IND Clearance by FDA Triggering Milestone Payment from Flexion to GeneQuine Biotherapeutics [ 12 Nov 2019 ]

Flexion’s IND application for FX201, which has the potential to provide long-term symptomatic relief and modify disease progression in knee osteoarthritis, was cleared by the FDA triggering a milestone payment from Flexion to GeneQuine. A Phase 1 single ascending dose study with FX201 has been initiated by Flexion and the first patient is expected to be treated by the end of 2019. GeneQuine believes that the FX201 IND approval will facilitate the transition of GeneQuine’s independent lead program GQ-303 from preclinical to clinical stage expected in 2021, as GQ-303 is also a gene therapy candidate for the treatment of osteoarthritis based on the same gene therapy vector technology.

More


US Patent Covering Gene Therapy Drug Candidates for Treatment of Osteoarthritis Issued [ 07 Jun 2019 ]

The U.S. Patent and Trademark Office (USPTO) grants a patent for FX201 (GeneQuine’s former human drug candidate GQ-203, acquired by Flexion Therapeutics, Inc.) and veterinary analogs for treatment of osteoarthritis.

More


GeneQuine Opens New Research and Development Site and Receives Grant [ 01 Apr 2019 ]

GeneQuine opens up a new research and development site in the greater Berlin area (state of Brandenburg, Germany) and receives a local government grant (GRW program) to support establishing the site.

More


GeneQuine on Expert Panel Discussion at Merck’s Advance Biotech Grant Program Award Ceremony, 31 January 2019, Darmstadt [ 29 Jan 2019 ]

As a previous winner of Mercks’s European Emerging Biotech Grant Program, GeneQuine’s CEO Kilian Guse will hold an introductory speech on how the grant accelerated GeneQuine's development of a novel gene therapy platform and supported the lead program in osteoarthritis.

More